A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs LY 3023703 (Primary) ; Celecoxib
- Indications Acute pain; Dental pain; Musculoskeletal pain
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 13 May 2013 New trial record